Joseph P. Balint

The Ad5 [E1-, E2b-]-based vector: a new and versatile gene delivery platform

Frank R. Jones, Elizabeth S. Gabitzsch, Joseph P. Balint, 2015, Sensing Technologies + Applications.

Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer

Frank R. Jones, Elizabeth S. Gabitzsch, Joseph P. Balint, 2015, Cancer Immunology, Immunotherapy.

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

Frank R. Jones, Elizabeth S. Gabitzsch, Joseph P. Balint, 2013, Cancer Immunology, Immunotherapy.

Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura

Joseph P. Balint, S. K. Cochran, H. W. Snyder, 1992 .